Urology
Volume 61, Issue 4, Supplement 1 , Pages 2-7 , April 2003

The role of dihydrotestosterone in benign prostatic hyperplasia

  • Culley Carson III

      Affiliations

    • Division of Urology, Department of Medicine, University of North Carolina, Chapel Hill North Carolina, USA (CC); Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, North Carolina, USA (RR)
    • C.C. Carson III is a member of the speaker’s bureau for, and is a study investigator funded by, GlaxoSmithKline.
    • Corresponding Author InformationReprint requests: Culley Carson III, MD, Division of Urology, Department of Medicine, University of North Carolina 2140, USA Bioinformatics Building, CB# 7235, Chapel Hill, North Carolina 27599-7235.
    • ,
  • Roger Rittmaster

      Affiliations

    • Division of Urology, Department of Medicine, University of North Carolina, Chapel Hill North Carolina, USA (CC); Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, North Carolina, USA (RR)

References 

  1. Meigs JB, Barry MJ. Natural history of benign prostatic hyperplasia. In:  Kirby R,  McConnell JD,  Fitzpatrick JM, et al. editor. Textbook of Benign Prostatic Hyperplasia. Oxford, UK: Isis Medical Media Ltd; 1996;p. 139–148
  2. Berry SJ, Coffey DS, Walsh PC, et al.  The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479
  3. Rane A. Endocrine and adrenergic pharmacological intervention in disease of the prostate. Br J Clin Pharmacol. 1998;45:329–337
  4. McConnell JD. 5 Alpha-reductase in prostate disease. In:  Kirby R,  McConnell JD,  Fitzpatrick JM, et al. editor. Textbook of Benign Prostatic Hyperplasia. Oxford, UK: Isis Medical Media Ltd; 1996;p. 85–90
  5. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol. 2000;37:367–380
  6. Buchanan G, Greenberg NM, Scher HI, et al.  Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res. 2001;7:1273–1281
  7. Snyder PG. Androgens. In:  Hardman JG,  Limbird LE editor. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001;p. 1635–1648
  8. Griffiths K, Morton MS, Nicholson RI. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur Urol. 1997;32(suppl 3):24–40
  9. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126:1165–1172
  10. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 1999;84:3463–3468
  11. Gnanapragasam VJ, Robson CN, Leung HY, et al.  Androgen receptor signaling in the prostate. BJU Int. 2000;86:1001–1013
  12. Griffiths K. Molecular control of prostate growth. In:  Kirby R,  McConnell JD,  Fitzpatrick JM, et al. editor. Textbook of Benign Prostatic Hyperplasia. Oxford, UK: Isis Medical Media Ltd; 1996;p. 23–26
  13. Foster CS. Pathology of benign prostatic hyperplasia. Prostate Suppl. 2000;9(suppl):4–14
  14. Iehle C, Radvanyi F, Gil Diez de Medina S, et al.  Differences in steroid 5α-reductase isoenzyme expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol. 1999;68:189–195
  15. Wilson JD. Androgens. In:  Hardman JG,  Limbird LE editor. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001;p. 1441–1458
  16. Imperato-McGinley J, Guerrero L, Gautier T, et al.  Steroid 5α-reductase deficiency in man (an inherited form of male pseudohermaphroditism). Science. 1974;186:1213–1215
  17. Wilson JD. The role of 5α-reduction in steroid hormone physiology. Reprod Fertil Dev. 2001;13:673–678
  18. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5:545–557
  19. Niu Y, Xu Y, Zhang J, et al.  Proliferation and differentiation of prostatic stromal cells. BJU Int. 2001;87:386–393
  20. Kim IY, Zelner DJ, Sensibar JA, et al.  Modulation of sensitivity to transforming growth factor-beta 1 and the level of type II TGF-β receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res. 1996;222:103–110
  21. Dutasteride tablets [package insert]. GlaxoSmithKline, Research Triangle Park, NC, 2002
  22. Finasteride tablets [package insert]. Merck & Company, Inc., Whitehouse Station, NJ, 2001
  23. Roehrborn CG, Boyle P, Nickel JC, et al.  Efficacy and safety of dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia (BPH). Urology. 2002;60:434–441
  24. McConnell JD, Bruskewitz R, Walsh P, et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–563

PII: S0090-4295(03)00045-1

doi: 10.1016/S0090-4295(03)00045-1

Urology
Volume 61, Issue 4, Supplement 1 , Pages 2-7 , April 2003

Article Tools

* Image Usage & Resolution